Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers
Norwalk virus-like particles (VLPs), made from recombinant capsid protein, are a promising vaccine. Thirty-six healthy adult volunteers received 250 microg (n = 10), 500 microg (n = 10), or 2000 microg (n = 10) of orally administered VLP or placebo (n = 6). All vaccinees developed significant rises...
| Veröffentlicht in: | Clinical immunology (Orlando, Fla.). - 1999. - 108(2003), 3 vom: 19. Sept., Seite 241-7 |
|---|---|
| 1. Verfasser: | |
| Weitere Verfasser: | , , , |
| Format: | Aufsatz |
| Sprache: | English |
| Veröffentlicht: |
2003
|
| Zugriff auf das übergeordnete Werk: | Clinical immunology (Orlando, Fla.) |
| Schlagworte: | Clinical Trial Journal Article Research Support, U.S. Gov't, P.H.S. Antibodies, Viral Immunoglobulin A, Secretory Immunoglobulin G Vaccines, Synthetic Viral Vaccines Interferon-gamma 82115-62-6 |
| Zusammenfassung: | Norwalk virus-like particles (VLPs), made from recombinant capsid protein, are a promising vaccine. Thirty-six healthy adult volunteers received 250 microg (n = 10), 500 microg (n = 10), or 2000 microg (n = 10) of orally administered VLP or placebo (n = 6). All vaccinees developed significant rises in IgA anti-VLP antibody-secreting cells. Ninety percent who received 250 microg developed rises in serum anti-VLP IgG; neither the rates of seroconversion nor geometric mean titers increased at the higher doses. About 30-40% of volunteers developed mucosal anti-VLP IgA. Lymphoproliferative responses and IFN-gamma production were observed transiently among those who received 250 microg or 500 microg but not 2000 microg of VLP. Studies to increase immunogenicity using a mucosal adjuvant are planned |
|---|---|
| Beschreibung: | Date Completed 30.10.2003 Date Revised 08.11.2019 published: Print Citation Status MEDLINE |
| ISSN: | 1521-7035 |